Skip to main content
. Author manuscript; available in PMC: 2017 Dec 1.
Published in final edited form as: Cancer Discov. 2016 Oct 11;6(12):1352–1365. doi: 10.1158/2159-8290.CD-16-0050

Figure 3.

Figure 3

(A) Relative changes in mutant allele fractions for various oncogenes implicated in MAPK signaling (red) pre-treatment and post-progression, with superimposed BRAFV600E cfDNA allele fraction (black). (B) Median nuclear: cytoplasmic ratios for ERK2 and FOXO3a as surrogate measures of MAPK and PI3K/Akt signaling for variants detected in plasma samples from patients at progression. Decreasing nuclear:cytoplasmic ratio for ERK2 and FOXO3a represents decreasing MAPK and increasing PI3K/Akt signaling, respectively.